Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NYSE:ELAN NASDAQ:GPCR NASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$74.95-0.8%$67.41$14.30▼$82.26$10.64B1.281.71 million shs1.40 million shsELANElanco Animal Health$21.77+2.1%$23.02$12.40▼$27.72$10.65B1.697.07 million shs5.83 million shsGPCRStructure Therapeutics$39.19+1.0%$46.77$15.80▼$94.90$2.75B-1.31844,079 shs732,468 shsPRAXPraxis Precision Medicines$343.56-2.0%$321.28$35.21▼$358.76$9.77B2.76398,647 shs249,965 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-0.78%-2.24%+1.39%+17.86%+389.55%ELANElanco Animal Health+2.17%+9.64%-3.21%-12.79%+72.28%GPCRStructure Therapeutics+1.03%+1.29%-15.72%-41.11%+62.28%PRAXPraxis Precision Medicines-2.00%+0.29%+1.86%+2.47%+811.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$74.95-0.8%$67.41$14.30▼$82.26$10.64B1.281.71 million shs1.40 million shsELANElanco Animal Health$21.77+2.1%$23.02$12.40▼$27.72$10.65B1.697.07 million shs5.83 million shsGPCRStructure Therapeutics$39.19+1.0%$46.77$15.80▼$94.90$2.75B-1.31844,079 shs732,468 shsPRAXPraxis Precision Medicines$343.56-2.0%$321.28$35.21▼$358.76$9.77B2.76398,647 shs249,965 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-0.78%-2.24%+1.39%+17.86%+389.55%ELANElanco Animal Health+2.17%+9.64%-3.21%-12.79%+72.28%GPCRStructure Therapeutics+1.03%+1.29%-15.72%-41.11%+62.28%PRAXPraxis Precision Medicines-2.00%+0.29%+1.86%+2.47%+811.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.75Moderate Buy$87.8017.14% UpsideELANElanco Animal Health 2.77Moderate Buy$28.2029.55% UpsideGPCRStructure Therapeutics 2.89Moderate Buy$109.25178.77% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$592.6772.51% UpsideCurrent Analyst Ratings BreakdownLatest GPCR, ARWR, ELAN, and PRAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026ARWRArrowhead Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)5/20/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.005/13/2026ARWRArrowhead Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$35.00 ➝ $46.005/13/2026PRAXPraxis Precision Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$700.00 ➝ $715.005/11/2026ELANElanco Animal Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/8/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$420.005/8/2026ARWRArrowhead Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$80.00 ➝ $87.005/8/2026PRAXPraxis Precision Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$130.00 ➝ $166.005/8/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.005/7/2026PRAXPraxis Precision Medicines Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/7/2026ELANElanco Animal Health CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $31.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$829.45M12.73$0.12 per share632.66$4.25 per share17.64ELANElanco Animal Health$4.72B2.31$2.37 per share9.19$13.01 per share1.67GPCRStructure TherapeuticsN/AN/AN/AN/A$20.43 per shareN/APRAXPraxis Precision Medicines$8.55M1,120.29N/AN/A$50.58 per share6.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$1.63M-$2.15N/AN/AN/A-48.38%-55.09%-18.13%8/6/2026 (Estimated)ELANElanco Animal Health-$232M-$0.50N/A17.992.29-4.95%7.42%3.66%8/6/2026 (Estimated)GPCRStructure Therapeutics-$141.20M-$0.87N/AN/AN/AN/A-24.91%-23.67%8/6/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)Latest GPCR, ARWR, ELAN, and PRAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q2 2026ARWRArrowhead Pharmaceuticals-$1.0950-$0.93+$0.1650-$0.93$73.84 million$73.74 million5/7/2026Q1 2026GPCRStructure Therapeutics-$0.39-$0.35+$0.04-$0.35$11.11 millionN/A5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/6/2026Q1 2026ELANElanco Animal Health$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion2/26/2026Q4 2025GPCRStructure Therapeutics-$0.35-$0.49-$0.14$999.00$7.14 millionN/A2/24/2026Q4 2025ELANElanco Animal Health$0.11$0.13+$0.02-$0.56$1.09 billion$1.14 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AELANElanco Animal HealthN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals1.416.236.23ELANElanco Animal Health0.602.161.12GPCRStructure TherapeuticsN/A26.1626.16PRAXPraxis Precision MedicinesN/A15.8815.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%ELANElanco Animal Health97.48%GPCRStructure Therapeutics91.78%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals3.60%ELANElanco Animal Health1.14%GPCRStructure Therapeutics5.60%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400140.86 million135.79 millionOptionableELANElanco Animal Health9,400499.45 million493.76 millionOptionableGPCRStructure Therapeutics13670.84 million66.88 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.13 millionOptionableGPCR, ARWR, ELAN, and PRAX HeadlinesRecent News About These CompaniesPraxis Precision Medicines' (PRAX) Buy Rating Reaffirmed at BTIG ResearchMay 21 at 3:15 AM | americanbankingnews.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by BrokeragesMay 19, 2026 | americanbankingnews.comIs FDA NDA Progress Amid Wider Losses Altering The Investment Case For Praxis Precision Medicines (PRAX)?May 18, 2026 | finance.yahoo.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $715.00 at Truist FinancialMay 14, 2026 | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Given New $715.00 Price Target at Truist FinancialMay 13, 2026 | marketbeat.comPraxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 12, 2026 | seekingalpha.comHC Wainwright Issues Pessimistic Outlook for PRAX EarningsMay 12, 2026 | marketbeat.comLifesci Capital Brokers Lower Earnings Estimates for PRAXMay 12, 2026 | marketbeat.comPraxis Precision Medicines Maps High-Stakes Launch PathMay 11, 2026 | tipranks.comWedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX)May 11, 2026 | insidermonkey.comUBS Group AG Sells 7,612 Shares of Praxis Precision Medicines, Inc. $PRAXMay 11, 2026 | marketbeat.comState of New Jersey Common Pension Fund D Acquires New Position in Praxis Precision Medicines, Inc. $PRAXMay 11, 2026 | marketbeat.comResearch Analysts Issue Forecasts for PRAX FY2030 EarningsMay 11, 2026 | marketbeat.comPraxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call TranscriptMay 9, 2026 | seekingalpha.comAnalysts Are Bullish on These Healthcare Stocks: Praxis Precision Medicines (PRAX), NewAmsterdam Pharma Company (NAMS)May 8, 2026 | theglobeandmail.comPraxis Precision Medicines Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $166.00May 8, 2026 | marketbeat.comBTIG Research Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)May 8, 2026 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Issues Earnings ResultsMay 7, 2026 | marketbeat.comPraxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | finanznachrichten.dePraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGPCR, ARWR, ELAN, and PRAX Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$74.95 -0.59 (-0.78%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$75.65 +0.70 (+0.93%) As of 05/22/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Elanco Animal Health NYSE:ELAN$21.77 +0.45 (+2.10%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$21.40 -0.36 (-1.67%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.Structure Therapeutics NASDAQ:GPCR$39.19 +0.40 (+1.03%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$38.34 -0.85 (-2.17%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Praxis Precision Medicines NASDAQ:PRAX$343.56 -7.00 (-2.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$341.96 -1.61 (-0.47%) As of 05/22/2026 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
